CD274 and neoplasm: Currently, PD-L1 expression, tumor mutational burden, and microsatellite instability-high (MSI-H) are recognized predictive biomarkers of treatment efficacy.[10] However, the heterogeneity of the tests used across studies and relative cutoffs limit their clinical application, especially the PD-L1 expression status.